Bakkaloğlu Ezgü, S. A. 2022. Lumasiran for patients with primary hyperoksaluria type 1 with impaired kidney function: Data from 6 month analysis of Phase 3 trial. 59. ERA Congres (Avrupa Nefroloji Kongresi) , (Paris, France), 837.

Bakkaloğlu Ezgü, S. A., (2022). Lumasiran for patients with primary hyperoksaluria type 1 with impaired kidney function: Data from 6 month analysis of Phase 3 trial . 59. ERA Congres (Avrupa Nefroloji Kongresi) (pp.837). Paris, France

Bakkaloğlu Ezgü, SEVCAN. "Lumasiran for patients with primary hyperoksaluria type 1 with impaired kidney function: Data from 6 month analysis of Phase 3 trial," 59. ERA Congres (Avrupa Nefroloji Kongresi), Paris, France, 2022

Bakkaloğlu Ezgü, SEVCAN A. . "Lumasiran for patients with primary hyperoksaluria type 1 with impaired kidney function: Data from 6 month analysis of Phase 3 trial." 59. ERA Congres (Avrupa Nefroloji Kongresi) , Paris, France, pp.837, 2022

Bakkaloğlu Ezgü, S. A. (2022) . "Lumasiran for patients with primary hyperoksaluria type 1 with impaired kidney function: Data from 6 month analysis of Phase 3 trial." 59. ERA Congres (Avrupa Nefroloji Kongresi) , Paris, France, p.837.

@conferencepaper{conferencepaper, author={SEVCAN AZİME BAKKALOĞLU EZGÜ}, title={Lumasiran for patients with primary hyperoksaluria type 1 with impaired kidney function: Data from 6 month analysis of Phase 3 trial}, congress name={59. ERA Congres (Avrupa Nefroloji Kongresi)}, city={Paris}, country={France}, year={2022}, pages={837} }